HK1248719A1 - 對her2和血腦屏障受體特異性的三特異性抗體及使用方法 - Google Patents

對her2和血腦屏障受體特異性的三特異性抗體及使用方法

Info

Publication number
HK1248719A1
HK1248719A1 HK18108169.8A HK18108169A HK1248719A1 HK 1248719 A1 HK1248719 A1 HK 1248719A1 HK 18108169 A HK18108169 A HK 18108169A HK 1248719 A1 HK1248719 A1 HK 1248719A1
Authority
HK
Hong Kong
Prior art keywords
her2
methods
brain barrier
antibodies specific
blood brain
Prior art date
Application number
HK18108169.8A
Other languages
English (en)
Inventor
Christian Klein
Julia Krueger
Ekkehard Moessner
Jens Niewoehner
Original Assignee
豪夫邁‧羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁‧羅氏有限公司 filed Critical 豪夫邁‧羅氏有限公司
Publication of HK1248719A1 publication Critical patent/HK1248719A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18108169.8A 2015-06-24 2018-06-26 對her2和血腦屏障受體特異性的三特異性抗體及使用方法 HK1248719A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15173640 2015-06-24
PCT/EP2016/064124 WO2016207091A1 (en) 2015-06-24 2016-06-20 Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use

Publications (1)

Publication Number Publication Date
HK1248719A1 true HK1248719A1 (zh) 2018-10-19

Family

ID=53489884

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108169.8A HK1248719A1 (zh) 2015-06-24 2018-06-26 對her2和血腦屏障受體特異性的三特異性抗體及使用方法

Country Status (6)

Country Link
US (3) US20180291110A1 (zh)
EP (1) EP3313890A1 (zh)
JP (1) JP7021955B2 (zh)
CN (1) CN107531788B (zh)
HK (1) HK1248719A1 (zh)
WO (1) WO2016207091A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113999312A (zh) 2015-06-24 2022-02-01 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20181004A1 (es) 2015-10-02 2018-06-26 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
BR112018069890A2 (pt) * 2016-05-02 2019-02-05 Hoffmann La Roche polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
MD3583120T2 (ro) 2017-02-17 2023-02-28 Denali Therapeutics Inc Polipeptide de legare la un receptor de transferină modificate
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JP2020510418A (ja) * 2017-02-17 2020-04-09 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． トランスフェリン受容体トランスジェニックモデル
US11866498B2 (en) * 2018-02-08 2024-01-09 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
AR114284A1 (es) * 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
SG11202101273VA (en) * 2018-08-16 2021-03-30 Denali Therapeutics Inc Engineered bispecific proteins
KR20210074279A (ko) * 2018-08-22 2021-06-21 데날리 테라퓨틱스 인크. 항-her2 폴리펩타이드 및 이의 사용방법
JP2023507846A (ja) 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
WO2021142269A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
WO2021142331A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
TW202144431A (zh) * 2020-02-19 2021-12-01 美商戴納立製藥公司 工程化抗her2雙特異性蛋白
US20230151115A1 (en) * 2020-03-31 2023-05-18 University Public Corporation Osaka Multispecific antibody and method for producing same
CN116574190A (zh) * 2021-07-30 2023-08-11 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023168531A1 (en) * 2022-03-09 2023-09-14 Immunofyx Anti-cancer n-terminal fc conjugated immunotherapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
WO2012091718A1 (en) * 2010-12-30 2012-07-05 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions and methods for treating cancer
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
KR102036262B1 (ko) 2012-08-29 2019-10-24 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
EA201890895A1 (ru) * 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
WO2015031673A2 (en) * 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2

Also Published As

Publication number Publication date
CN107531788B (zh) 2022-06-21
US20230212312A1 (en) 2023-07-06
US20180291110A1 (en) 2018-10-11
JP2018522549A (ja) 2018-08-16
EP3313890A1 (en) 2018-05-02
CN107531788A (zh) 2018-01-02
US20200299407A1 (en) 2020-09-24
WO2016207091A1 (en) 2016-12-29
JP7021955B2 (ja) 2022-03-03

Similar Documents

Publication Publication Date Title
HK1248719A1 (zh) 對her2和血腦屏障受體特異性的三特異性抗體及使用方法
IL252055A0 (en) Blood brain barrier receptor antibodies and methods of use
HK1223954A1 (zh) 雙特異性抗-半抗原/抗-血腦屏障受體的抗體、其複合物及它們作為血腦屏障穿梭物的應用
HK1248773A1 (zh) 用於癌症的治療和診斷方法
HK1250376A1 (zh) 用於癌症的治療和診斷方法
HK1250513A1 (zh) 抗ox40抗體及其使用方法
IL250887A0 (en) Methods of treating a disease or disorder by an oral formulation of cytidine analogs in combination with an anti-pd1 or anti-pdl1 monoclonal antibody
GB201617190D0 (en) Apparatus and associated methods for tracking and increasing medication adherence for patients
HK1247143A1 (zh) 用於製備並施用血液組分的儀器和方法
PT3110848T (pt) Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
PL3824929T3 (pl) Kaniula z pięcioma skosami do urządzeń do pobierania krwi
EP3230439C0 (en) HUMAN BLOOD-BRAIN BARRIER MODEL
IL267622A (en) Method for modifying the therapeutic effects of drugs
GB2566663B (en) Intraoperative medical imaging method and system
HK1258128A1 (zh) 選擇病人接受組合療程
PT3495352T (pt) Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas
IL254706B (en) A medical system for penetrating the anatomical structure of patients
HK1223630A1 (zh) 抗- 療法的實施與用量
HUE054716T2 (hu) Anti-EGFR-t tartalmazó gyógyászati készítmény
GB201500875D0 (en) Antibodies for treatment and diagnosis
IL250146A0 (en) Methods for determining drug response of patient-specific mutations
IL246913B (en) Methods for treating dermatitis by administering an antagonist to -il-4r
GB201509827D0 (en) Antibody drug conjugate for treatment of cancer
AU364590S (en) Clip for patient interface
GB201415182D0 (en) Process for preparation of blood group antigen derivatives